ReviewMedicine2026
Bibliometric analysis of cognitive impairment secondary to chronic kidney disease.
Review in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCognitive impairment (CI) is a common complication in chronic kidney disease (CKD) patients, affecting 10% to 50% of individuals depending on disease stage. Despite its clinical significance, the molecular mechanisms remain unclear, and effective interventions are lacking. This bibliometric analysis aimed to comprehensively map the research landscape of CI secondary to CKD from 1995 to 2024, identifying trends, key contributors, and evolving foci.
methodsA total of 1783 English original articles and reviews were retrieved from the Web of Science Core Collection. Bibliometric analysis was performed using R-bibliometrix (v4.4.2), CiteSpace (v6.3.1), and Excel 2024. Metrics included annual publications, country/affiliation contributions, journal impact (H-index, Bradford Law), citation analysis (local/global citations), author influence (H-index), keyword co-occurrence, burst detection, and thematic evolution.
resultsPublications surged after 2016, with the United States leading output (nearly 500 articles) and collaborations. The University of California System was the top affiliation (n = 243). Core journals were Nephrology Dialysis Transplantation, American Journal of Kidney Diseases, and Clinical Journal of the American Society of Nephrology. Yaffe K was the most influential author (H-index = 19). Key articles by Kurella M and Murray AM were highly cited. Keyword analysis revealed shifting themes: early research focused on prevalence and clinical associations, while current hotspots emphasized molecular mechanisms (α-Klotho, NLRP3 inflammasome) and comorbidities (fatty liver disease).
conclusionsResearch on CKD-associated CI has expanded significantly, with a paradigm shift toward mechanistic exploration. The USA dominates scholarly output, and interdisciplinary collaboration is critical. Emerging themes highlight the roles of inflammation, metabolic dysregulation, and organ crosstalk. These insights inform future research directions, clinical screening strategies, and therapeutic targeting for CI in CKD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.